



IMAC Holdings, Inc.

Corporate Presentation :: Fall 2021



Safe Harbor Statements

This presentation, including the accompanying oral presentation (collectively, this "presentation"), does not constitute an offer to sell or a solicitation of an offer to buy any securities. This presentation is provided by IMAC Holdings, Inc. ("IMAC") for informational purposes only and should be kept confidential. No representations express or implied are being made by IMAC or any other person as to the accuracy or completeness of the information contained herein.

This presentation contains "forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other legal authority. Forward-looking statements include statements about scalability, growing distribution channels, credit predictability and information concerning our future financial performance, business plans and objectives, potential growth opportunities, financing plans, competitive position, industry environment and potential market opportunities. Forward-looking statements can also be identified by words such as "will," "enables", "expects", "may", "allows", "continues", "believes," "intends," "anticipates," "estimates" or similar expressions. Forward-looking statements are neither historical facts nor assurances of future performance. They are based only on our current beliefs, expectations and assumptions regarding the future of our business, anticipated events and trends, the economy and other future conditions. Moreover, we do not assume responsibility for the accuracy and completeness of forward-looking statements. As such, they are subject to inherent uncertainties, changes in circumstances, known and unknown risks and other factors that are difficult to predict and in many cases outside our control. Past performance does not guarantee future results.

As a result, you should not rely on any forward-looking statements. Our expected results may not be achieved, and actual results may differ materially from our forward-looking statements. Important factors that could cause actual results to differ from our forward-looking statements are the risks that we may not be able to manage our anticipated or actual growth effectively, that our models do not adequately identify potential risks and other risks. We undertake no obligation to publicly update any forward-looking statements for any reason after the date of this presentation to confirm these statements to actual results or to changes in our expectations, except as required by law.

IMAC Holdings, Inc.

Nasdaq: IMAC

\$11.2m cash*

\$3.0m AP, NP & Accrued Expenses*

25.3m shares outstanding*

\$1.32 share price**

* September 30, 2021 10Q filing

** November 15, 2021 closing share price

IMAC Regeneration Centers

Outpatient Medical Clinics

Research Division

Clinical Trial

the **BACKSPACE**

Retail Chiropractic Centers

IMAC

REGENERATION CENTERS



IMAC Holdings, founded in 2015, owns and manages 18 outpatient clinics delivering orthopedic, regenerative, and minimally invasive procedures and therapies for movement-restricted conditions

Revenue:

65% Medical

31% Physical Therapy

4% Chiropractic

Medical Professionals:

19 Medical

19 Physical Therapy

15 Chiropractic

Locations:

Illinois (3): Arlington Heights, Elgin, Naperville

Kentucky (3): Lexington, Murray, Paducah

Missouri (6): Chesterfield, Ozark, Springfield

(2), St. Peters, Webster Groves

Locations:

Florida (4): Bonita Springs, Ft. Pierce, Orlando, Tampa

Louisiana: Baton Rouge

Tennessee: Brentwood

TTM Acquisitions

November, 2020: St. Louis

February: Tampa


March: Orlando

June: Ft. Pierce

June: Naperville

October: Baton Rouge

IMAC Clinic Locations




- Target acquisitions at under 2x multiple of cash flow.
- Calculation adjusted for replacement staff
- Small acquisitions require equipment, staffing, and/or space modifications which may impact timing to

Phase I Clinical Trial

- Investigator-initiated trial; IMAC medical doctors approved as Investigators for trial
- Opens door to possible Regenerative Medicine Advanced Therapy designation and research grant
- 15-patient trial conducted in 3 IMAC clinics during 12-month study
- First patient dose administered December, 2020
- Completion of first cohort of trial February, 2021
- Second cohort start of trial started August, 2021



**Mesenchymal Stem Cells
for Bradykinesia due to
Parkinson's Disease**



the **BACKSPACE**

- Walk-in spinal health and wellness
- \$4,000,000 from recent funding to launch brand and storefronts
- 10 store test market with Walmart
- First store opened in May, 2021
- Cash based services \$25 each
 - Manual Chiropractic Adjustment
 - Percussion Therapy
 - Muscle Stimulation
- Monthly Membership for \$65 includes 4 services per month

→ Investment Summary

Recent growth targeting clinics at COVID-impacted valuations expected to improve future performance

Strategic initiatives with proprietary neurological research may create partnership opportunities

IMAC is positioned to leverage large and growing market with treatments directed toward the aging population

Consolidation of fragmented chiropractic industry for affordable and accessible spinal health and wellness for most afflicted population

